RET and non-small cell lung carcinoma: Intracranial ORR after the fixed effects model was 0.86 (95%CI: 0.74 ~ 0.96, P < 0.05), indicating that RET fusion gene-positive NSCLC with intracranial metastasis still has an excellent response to drugs (Fig. 5).